Organoids, three-dimensional (3D) multicellular structures that closely emulate organ architecture and function, are cultivated in vitro from both pluripotent and adult stem cells1–3. The development of organoids has transformed them into essential resources for a broad spectrum of biological research targeting various organs, such as the intestine4,5, lung6,7, liver8–10, kidney11,12, and brain13,14. These three-dimensional organ models surpass the conventional two-dimensional cell culture methods by closely replicating the natural architecture and organization of cells as found in living organisms. Organoids are formed when progenitor cells, sourced from an organ's adult stem cells or induced pluripotent stem cells, undergo differentiation and organization into structures that resemble organ function and structure, mirroring the organ development process in nature. This methodology ensures that organoids retain the cellular and molecular properties more faithfully compared to traditional cell cultures. By closely simulating conditions within a living organism, organoids have become pivotal in disease modeling, facilitating the exploration of disease mechanisms and the evaluation of new drugs and therapeutic approaches3.
Imaging plays a crucial role in unraveling the complexity of organoids, revealing their morphology and confirming their accurate representation of in vivo counterparts. The use of thin sectioning along with traditional staining has been widely employed to examine tissue architecture in 2D and to analyze the distribution of single and multiple stained biomarkers. Although brightfield microscopy remains instrumental for organoid visualization, this methodology falls short in capturing their 3D complexity. More advanced modalities, including confocal, multiphoton, and light-sheet microscopy, offer improved 3D imaging but come with their own caveats—namely, the necessity for fluorescent labeling of samples and potential phototoxic effects15,16. Consequently, there is an ongoing quest for advanced imaging technologies that can provide high-resolution views, deep tissue penetration, and real-time observation of dynamic cellular changes of organoids, all without requiring time consuming sample preparation, labeling, and imaging17.
In recent years, quantitative phase imaging (QPI) has gained recognition as a technique for the label-free imaging of live biological samples18–22. Within this realm, holotomography (HT)—a 3D extension of QPI—offers a unique advantage by enabling real-time capture of cellular dynamics in organoids without the drawbacks of phototoxicity or photobleaching. In this work, we employ low-coherence HT for the sustained, label-free monitoring of organoids, shedding light on their developmental trajectories and pharmacological responses. Utilizing mouse small intestinal organoids (sIOs) as our organoid imaging model system, we achieved time-lapse imaging for a duration exceeding 120 hours. This approach allowed us to observe growth patterns, capture detailed subcellular structures with a lateral resolution of 155 nm and an axial resolution of 947 nm, and quantitatively evaluate the organoids' responsiveness to drug treatments. Low-coherence HT was uniquely effective in distinguishing between viable and non-viable cells within the organoids, and offered unparalleled details in depicting 3D morphological shifts following drug exposure. The method further allowed quantitative measurements of organoid volume, protein concentration, and dry mass, setting a new standard for comprehensive, rigorous statistical assessments for the biological studies of organoids.